ICH GCP R3 is now in English & EU languages. Book Now

About

Our Good Pharmacovigilance Practice (GVP) online training platform allows you to access our courses from wherever you are. Get trained and certified at your convenience. If you are involved in any aspect of pharmacovigilance (GVP), our four-course modules will help you comply with European and US laws. The modules are ideal for professionals involved in drug safety, pharmacovigilance, regulatory affairs, and quality compliance. The Pharmacovigilance Signalling and Risk Assessment course is recommended for those involved in drug safety, clinical trials, pharmacoepidemiology, and risk management. The Pharmacovigilance Signalling and Risk Assessment course covers key components of signal detection, including definitions, objectives, examples, FDA risk management components, EU signalling requirements, and data-mining principles. Each of these factors is crucial for a company to ensure compliance with legislation. One of the primary objectives of signalling and risk management is to understand and manage the risk profiles of drugs to help avoid extremely expensive and damaging drug withdrawals. Pharmacovigilance Signalling and Risk Assessment is a valuable addition to your pharmacovigilance knowledge when combined with the Pharmacovigilance Audit course. The course includes interactive mini-exams at the end of each chapter to help reinforce learning.

This course comprehensively explains signalling and risk assessment in pharmacovigilance, including an overview of data mining, signal detection, and regulatory requirements across European and American markets. Keeping products on the market without interruption has become more essential due to the reduced pipeline of drugs in development. Successful navigation of drug safety and pharmacovigilance is key to product longevity, consumer confidence, and regulatory compliance. This module provides a strong foundation of knowledge in pharmacovigilance and drug safety.

Course Syllabus

  1. Learning Objectives for This Module

  1. What Is Pharmacovigilance?
  2. What Is a Signal?
  3. Need for Signal Detection
  4. Increased Withdrawals (1998–2001)

  1. Reason for Change
  2. Rezulin Withdrawal
  3. Baycol Withdrawal
  4. The Cost of Failure

  1. FDA Risk Management Components
  2. FDA Amendment Act (FDAAA)
  3. European Signalling Requirements
  4. GVP Module IX – Signal Management
  5. MHRA & Signal Detection
  6. EudraVigilance Monitoring

  1. Signal Detection Objectives
  2. AE Incidence Rate
  3. Numerator (AEs)
  4. Denominator (Patient Exposure)
  5. Rates
  6. Premise
  7. Need for the Prepared Mind
  8. CIOMS VIII Report
  9. Signal Detection Hierarchy

  1. Signalling Analyses
  2. Approach to Signal Detection – Small Companies
  3. Approach to Signal Detection – Large Companies
  4. Data Extraction and Visualization
  5. Data Flow
  6. PSUR Prior to Analysis
  7. Sector Map by SOC
  8. Sector Map by PT
  9. Analysis by Cause of Death
  10. Analysis by Preferred Term I
  11. Analysis by Preferred Term II
  12. Analysis by Preferred Term III
  13. Analysis by Age Range
  14. Analysis by Sex
  15. Analysis by Country
  16. Analysis by Time to Onset
  17. Analysis by Treatment Duration
  18. Analysis by AE Duration
  19. Analysis by Concomitant Medications
  20. Analysis by Concomitant Medications II
  21. Hypotheses

  1. What Is Data Mining?
  2. Principles of Safety Data Mining
  3. Data Mining Challenge
  4. Recommended Approach – Large Companies

  1. Data Mining Methods
  2. Information Component (IC)
  3. Bayesian Confidence Propagation Neural Network (BCPNN)
  4. PSUR Data
  5. IC Scores: PSUR
  6. Increased frequency analysis of PTs from company PSUR
  7. Comparison of increased frequency of company reports to IC scores in FDA AERS
  8. SDRs to be investigated
  9. Multi-item Gamma Poisson Shrinker (MGPS)
  10. Proportional Reporting Ratio (PRR)
  11. PRR example
  12. Final conclusion

Course Benefits

Benefits cpd_points icon
CPD Points

Gain Continuing Professional Development (CPD) Points, accredited by The Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. These can be used to count towards the distance learning element of any scheme that comes under the umbrella of The Academy of Medical Royal Colleges or any other scheme for which there is mutual recognition.

Benefits certification icon
Certification

Receive a personal certificate to show your subject knowledge on course completion.

Benefits affordable icon
Affordable

You get excellent value through our cost-effective prices. We can also offer you group discounts on larger purchases.

Benefits flexible icon
Flexibility

The course saves you time through the convenience of online availability. This lets you complete the interactive course at your own comfort.

Benefits up_to_date icon
Keep Up to Date

You will stay up to date with any legislative changes in pharmacovigilance as our training courses are constantly monitored, reviewed and updated.

Benefits industry_experts icon
Learn from Industry Experts

The course content has been developed to ensure that you comply with pharmacovigilance legislation through the application of learning outcomes. The course is written by Steve Jolley, who is a chairperson for the Drug Information Association (DIA)


Our Certified Customers

novartis
NHS
takeda
roche
dhl

Learner Rating & Reviews

4.7
Average Rating
536 global ratings
87.0%
5.0%
3.0%
3.0%
2.0%
RC

Working with Whitehall training for the last two years of partnership has been a very successful experience – I have fast access to all the GCP course...

SM

I have finalised the demo for the ICH-GCP E6 R3 refresher course. Overall, I liked the content and the interface. I also want to thank Whitehall Train...